# A First-in-Human Safety and Pharmacokinetic Trial of GenSci142 Administered as Single Ascending Doses in Healthy Chinese Women

> **NCT07302035** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Bacterial Vaginosis

## Interventions

- **DRUG:** GenSci142
- **DRUG:** Placebo GenSci142

## Key facts

- **NCT ID:** NCT07302035
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2026-09
- **Final completion:** 2026-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07302035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07302035, "A First-in-Human Safety and Pharmacokinetic Trial of GenSci142 Administered as Single Ascending Doses in Healthy Chinese Women". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT07302035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*